SingVax develops prophylactic vaccines for infectious diseases relevant to the Asia Pacific region. To maximise the company's value, SingVax targets vaccine candidates for substantial medical needs and products that have immediate entry to clinical development.

SingVax has established its in-house vaccine development infrastructure. The company has three products in development.
 

These are:

Chikungunya(CHIKV) vaccine to address this viral disease.

Japanese Encephalitis (JE) vaccine for the prevention of JE virus infection

Enterovirus 71 (EV71) vaccine for the prevention of EV71 infection

SingVax protects its products, through a rigorous intellectual property strategy. The company has already filed for a patent application and will continue to seek further patenting opportunities on its product portfolio during development.